Content deleted Content added
consistent citation formatting |
85.255.232.229 (talk) Typo Tags: Reverted references removed Visual edit Mobile edit Mobile web edit |
||
Line 31: | Line 31: | ||
}} |
}} |
||
'''Dipraglurant''' ([[International Nonproprietary Name|INN]]) (code name '''ADX-48621''') is a [[negative allosteric modulator]] of the [[mGlu5 receptor|mGlu<sub>5</sub> receptor]] which is under development by [[Addex Therapeutics]] for the treatment of [[Parkinson's disease]] [[levodopa-induced dyskinesia]] (PD-LID).<ref name="MartinezGil2013">{{cite book | vauthors = Martinez A, Gil C |title=Emerging Drugs and Targets for Parkinson's Disease|url=https://books.google.com/books?id=g3_8KlQvenAC&pg=PA255|date=29 July 2013|publisher=Royal Society of Chemistry|isbn=978-1-84973-617-6|pages=255–}}</ref><ref name="Macor2012">{{cite book| vauthors = Macor JE |title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=xpe9Mk50BGsC&pg=PA83|year=2012|publisher=Academic Press|isbn=978-0-12-396492-2|pages=83–}}</ref><ref name="FoxBrotchie2014">{{cite book| vauthors = Fox SH, Brotchie JM |title=Levodopa-Induced Dyskinesia in Parkinson's Disease|url=https://books.google.com/books?id=ME69BAAAQBAJ&pg=PA323|date=8 October 2014|publisher=Springer|isbn=978-1-4471-6503-3|pages=323–}}</ref> As of 2014, it is in [[Phases of clinical research|phase II]] [[clinical trial]]s for this indication.<ref name="MartinezGil2013" /> Addex Therapeutics is also investigating an [[extended-release formulation]] of dipraglurant for the treatment |
'''Dipraglurant''' ([[International Nonproprietary Name|INN]]) (code name '''ADX-48621''') is a [[negative allosteric modulator]] of the [[mGlu5 receptor|mGlu<sub>5</sub> receptor]] which is under development by [[Addex Therapeutics]] for the treatment of [[Parkinson's disease]] [[levodopa-induced dyskinesia]] (PD-LID).<ref name="MartinezGil2013">{{cite book | vauthors = Martinez A, Gil C |title=Emerging Drugs and Targets for Parkinson's Disease|url=https://books.google.com/books?id=g3_8KlQvenAC&pg=PA255|date=29 July 2013|publisher=Royal Society of Chemistry|isbn=978-1-84973-617-6|pages=255–}}</ref><ref name="Macor2012">{{cite book| vauthors = Macor JE |title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=xpe9Mk50BGsC&pg=PA83|year=2012|publisher=Academic Press|isbn=978-0-12-396492-2|pages=83–}}</ref><ref name="FoxBrotchie2014">{{cite book| vauthors = Fox SH, Brotchie JM |title=Levodopa-Induced Dyskinesia in Parkinson's Disease|url=https://books.google.com/books?id=ME69BAAAQBAJ&pg=PA323|date=8 October 2014|publisher=Springer|isbn=978-1-4471-6503-3|pages=323–}}</ref> As of 2014, it is in [[Phases of clinical research|phase II]] [[clinical trial]]s for this indication.<ref name="MartinezGil2013" /> Addex Therapeutics is also investigating an [[extended-release formulation]] of dipraglurant for the treatment the Olly of the bolly is so cool |
||
==See also== |
==See also== |
Revision as of 13:43, 14 June 2021
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H12FN3 |
Molar mass | 265.291 g·mol−1 |
3D model (JSmol) | |
| |
|
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment the Olly of the bolly is so cool
See also
References
- ^ a b Martinez A, Gil C (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
- ^ Macor JE (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
- ^ Fox SH, Brotchie JM (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
External links
- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
- Dipraglurant-ER for dystonia - Addex Therapeutics